Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.37 |
| ▸ | CDK2 | P24941 | 5/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.35 |
| ▸ | CCND1 | P24385 | 3/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190838 | 1.00 | ERN1 (0.56) | ERN1CCNE1CDK2CCNE2MAPK8 | |
| SCHEMBL29358655 | 1.00 | ERN1 (0.56) | ERN1CCNE1CDK2CCNE2MAPK8 | |
| SCHEMBL22190574 | 0.95 | ERN1 (0.56) | ERN1CCNE1CDK2CCNE2MAPK8 | |
| SCHEMBL22190571 | 0.95 | ERN1 (0.56) | ERN1CCNE1CDK2CCNE2MAPK8 | |
| SCHEMBL22191666 | 0.90 | ERN1 (0.46) | ERN1CCNE1CDK2CCNE2MAPK8 | |
| SCHEMBL22191339 | 0.89 | ERN1 (0.60) | ERN1CCNE1CDK2CCNE2MAPK8 | |
| SCHEMBL22191338 | 0.89 | ERN1 (0.60) | ERN1CCNE1CDK2CCNE2MAPK8 | |
| SCHEMBL25035562 | 0.89 | ERN1 (0.63) | ERN1CCNE1CDK2CCNE2MAPK8 | |
| SCHEMBL22191222 | 0.88 | ERN1 (0.64) | ERN1CCNE1CDK2CCNE2MAPK8 | |
| SCHEMBL22200501 | 0.88 | ERN1 (0.64) | ERN1CCNE1CDK2CCNE2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
| WO-2020142612-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. | GENENTECH, INC. (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | ERN1 3167/4885CCNE1 1158/4885CDK2 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.